Search results
Results from the WOW.Com Content Network
AERD affects an estimated 0.3–0.9% of the general population in the US, including around 7% of all asthmatics, about 14% of adults with severe asthma, and ~5-10% of patients with adult onset asthma. [2] [3] [8] AERD is uncommon among children, with around 6% of patients, predominantly female, reporting disease onset during childhood. [9]
The classification organizes the hypersensitivity reactions to NSAIDs into the following five categories: NSAIDs-exacerbated respiratory disease (NERD) is an acute (immediate to several hours) exacerbation of bronchoconstriction and other symptoms of asthma in individuals with a history of asthma and/or nasal congestion, rhinorrhea or other symptoms of rhinitis and sinusitis in individuals ...
An allergic reaction will not occur on the first exposure to a substance. The first exposure allows the body to create antibodies and memory lymphocyte cells for the antigen. However, drugs often contain many different substances, including dyes, which could cause allergic reactions. This can cause an allergic reaction on the first ...
[10] Type II hypersensitivity. Damage can be accomplished via three different mechanisms: [10] Antibody binding to cell surface receptors and altering its activity; Activation of the complement pathway. Antibody-dependent cellular cytotoxicity. The pathophysiology of type II hypersensitivity reactions can be broadly classified into three types ...
Allergic inflammation is an important pathophysiological feature of several disabilities or medical conditions including allergic asthma, atopic dermatitis, allergic rhinitis and several ocular allergic diseases. Allergic reactions may generally be divided into two components; the early phase reaction, and the late phase reaction.
Xolair, which is developed and co-promoted by Genentech and Novartis in the US, was originally approved in 2003 for the treatment of moderate to severe persistent allergic asthma in certain people.
Mast cell activation syndrome (MCAS) is a term referring to one of two types of mast cell activation disorder (MCAD); the other type is idiopathic MCAD. [1] MCAS is an immunological condition in which mast cells, a type of white blood cell, inappropriately and excessively release chemical mediators, such as histamine, resulting in a range of chronic symptoms, sometimes including anaphylaxis or ...
People with atopic diseases such as asthma, eczema, or allergic rhinitis are at high risk of anaphylaxis from food, latex, and radiocontrast agents but not from injectable medications or stings. [3] [10] One study in children found that 60% had a history of previous atopic diseases, and of children who die from anaphylaxis, more than 90% have ...